JP2007511616A - 増強された薬物送達 - Google Patents

増強された薬物送達 Download PDF

Info

Publication number
JP2007511616A
JP2007511616A JP2006541595A JP2006541595A JP2007511616A JP 2007511616 A JP2007511616 A JP 2007511616A JP 2006541595 A JP2006541595 A JP 2006541595A JP 2006541595 A JP2006541595 A JP 2006541595A JP 2007511616 A JP2007511616 A JP 2007511616A
Authority
JP
Japan
Prior art keywords
lipid
particles
encapsulated
target
particle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2006541595A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007511616A5 (cg-RX-API-DMAC7.html
Inventor
ランザ、グレゴリー、エム.
ウィクライン、サムエル、エイ.
Original Assignee
バーンズ−ジューイッシュ ホスピタル
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バーンズ−ジューイッシュ ホスピタル filed Critical バーンズ−ジューイッシュ ホスピタル
Publication of JP2007511616A publication Critical patent/JP2007511616A/ja
Publication of JP2007511616A5 publication Critical patent/JP2007511616A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0047—Sonopheresis, i.e. ultrasonically-enhanced transdermal delivery, electroporation of a pharmacologically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
    • A61K47/6909—Micelles formed by phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0404—Lipids, e.g. triglycerides; Polycationic carriers
    • A61K51/0408—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1217—Dispersions, suspensions, colloids, emulsions, e.g. perfluorinated emulsion, sols
    • A61K51/1227—Micelles, e.g. phospholipidic or polymeric micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2006541595A 2003-11-19 2004-11-19 増強された薬物送達 Withdrawn JP2007511616A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52383303P 2003-11-19 2003-11-19
PCT/US2004/039095 WO2005051305A2 (en) 2003-11-19 2004-11-19 Enhanced drug delivery

Publications (2)

Publication Number Publication Date
JP2007511616A true JP2007511616A (ja) 2007-05-10
JP2007511616A5 JP2007511616A5 (cg-RX-API-DMAC7.html) 2007-11-29

Family

ID=34632831

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006541595A Withdrawn JP2007511616A (ja) 2003-11-19 2004-11-19 増強された薬物送達

Country Status (7)

Country Link
US (1) US20050175541A1 (cg-RX-API-DMAC7.html)
EP (1) EP1684724A4 (cg-RX-API-DMAC7.html)
JP (1) JP2007511616A (cg-RX-API-DMAC7.html)
AU (1) AU2004293027A1 (cg-RX-API-DMAC7.html)
CA (1) CA2540621A1 (cg-RX-API-DMAC7.html)
IL (1) IL174690A0 (cg-RX-API-DMAC7.html)
WO (1) WO2005051305A2 (cg-RX-API-DMAC7.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012508190A (ja) * 2008-11-07 2012-04-05 クロクス テクノロジーズ インコーポレイテッド ヒアルロン酸、グルコサミン、およびアラントインを含む、酸化的光活性化皮膚再生組成物
JP2012533522A (ja) * 2009-07-17 2012-12-27 クロクス テクノロジーズ インコーポレイテッド 口腔内消毒および口腔疾患の処置のための酸化剤、光増感剤および創傷治癒剤の組み合わせ

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006044996A2 (en) * 2004-10-15 2006-04-27 The Trustees Of Columbia University In The City Of New York System and method for automated boundary detection of body structures
US8153435B1 (en) 2005-03-30 2012-04-10 Tracer Detection Technology Corp. Methods and articles for identifying objects using encapsulated perfluorocarbon tracers
AU2006235421A1 (en) * 2005-04-08 2006-10-19 Cytogen Corporation Conjugated anti-PSMA antibodies
KR20080028361A (ko) * 2005-05-03 2008-03-31 뮤추얼 파마슈티컬 컴퍼니 아이엔씨. 퀴닌-함유 제어-방출형 제제
US10687785B2 (en) 2005-05-12 2020-06-23 The Trustees Of Columbia Univeristy In The City Of New York System and method for electromechanical activation of arrhythmias
WO2006126244A1 (ja) * 2005-05-23 2006-11-30 Mebiopharm Co., Ltd. ガス封入リポソームの製造法
US20110135725A1 (en) * 2005-05-23 2011-06-09 Sdg, Inc. Lipid Construct for Delivery of Insulin to a Mammal
EP1937151A4 (en) * 2005-09-19 2011-07-06 Univ Columbia Systems and methods for opening of the blood-brain barrier of a subject using ultrasound
WO2007044748A2 (en) * 2005-10-11 2007-04-19 University Of Pittsburgh Sphingomyelin liposomes for the treatment of hyperactive bladder disorders
CN103767886B (zh) 2005-11-09 2018-04-24 科洛斯科技公司 使牙齿增白的组合物及方法
WO2007067987A2 (en) * 2005-12-09 2007-06-14 The Trustees Of Columbia University In The City Ofnew York Systems and methods for elastography imaging
US20100183726A1 (en) * 2006-08-02 2010-07-22 Robert Nicolosi Compositions and methods for treating cancer with dacarbazine nanoemulsions
NO20064315L (no) 2006-09-22 2008-03-24 Epitarget As T1 MRI-sporbare medikamentavleveringspartikler and anvendelse derav
US7947262B2 (en) * 2006-09-26 2011-05-24 Virginia Commonwealth University Use of fullerenes for the treatment of mast cell and basophil-mediated disease
US20100266989A1 (en) 2006-11-09 2010-10-21 Klox Technologies Inc. Teeth whitening compositions and methods
CZ2006743A3 (cs) * 2006-11-28 2008-03-26 Fyziologický ústav AV CR Liposomální gelový ftalocyaninový prípravek pro fotodynamickou terapii nádorových onemocnení a zpusob jeho prípravy
JP5249248B2 (ja) 2007-03-05 2013-07-31 ワシントン ユニバーシティー 膜組み込みペプチドのためのナノ粒子輸送システム
US8962015B2 (en) 2007-09-28 2015-02-24 Sdg, Inc. Orally bioavailable lipid-based constructs
GB0721081D0 (en) 2007-10-26 2007-12-05 Metcalfe Susan M Immuno-modulatory composition
WO2009110939A2 (en) * 2007-12-10 2009-09-11 Massachusetts Institute Of Technology Drug delivery system for pharmaceuticals and radiation
US20100009424A1 (en) * 2008-07-14 2010-01-14 Natasha Forde Sonoporation systems and methods
WO2010014977A1 (en) 2008-08-01 2010-02-04 The Trustees Of Columbia University In The City Of New York Systems and methods for matching and imaging tissue characteristics
WO2010030819A1 (en) 2008-09-10 2010-03-18 The Trustees Of Columbia University In The City Of New York Systems and methods for opening a tissue
US20100178244A1 (en) * 2009-01-13 2010-07-15 Arnsdorf Morton F Biocompatible Microbubbles to Deliver Radioactive Compounds to Tumors, Atherosclerotic Plaques, Joints and Other Targeted Sites
US20100178245A1 (en) * 2009-01-13 2010-07-15 Arnsdorf Morton F Biocompatible Microbubbles to Deliver Radioactive Compounds to Tumors, Atherosclerotic Plaques, Joints and Other Targeted Sites
US10058837B2 (en) 2009-08-28 2018-08-28 The Trustees Of Columbia University In The City Of New York Systems, methods, and devices for production of gas-filled microbubbles
US20110129424A1 (en) * 2009-09-16 2011-06-02 Cory Berkland Fluorinated polymers and associated methods
EP2480144B1 (en) 2009-09-21 2024-03-06 The Trustees of Columbia University in the City of New York Systems for opening of a tissue barrier
EP2512588A4 (en) * 2009-12-16 2014-06-04 Univ Columbia METHODS, DEVICES AND SYSTEMS FOR ULTRASOUND-RELEASED ON-DEMAND AGGREGATE FREEZING
US20110150986A1 (en) * 2009-12-18 2011-06-23 Kristin Arnold Quinine formulations, method of making, and metho of use thereof
ES2564502T3 (es) 2010-03-17 2016-03-23 Novaliq Gmbh Composición farmacéutica para el tratamiento de la presión intraocular aumentada
EP2444063A1 (en) 2010-10-20 2012-04-25 Novaliq GmbH Liquid pharmaceutical compositions for the delivery of active ingredients
EP2462921A1 (en) 2010-11-11 2012-06-13 Novaliq GmbH Liquid pharmaceutical compositions for the treatment of a posterior eye disease
EP2661280B1 (en) * 2011-01-04 2018-11-21 Novaliq GmbH O/w-emulsions comprising semifluorinated alkanes
WO2012135550A1 (en) * 2011-03-30 2012-10-04 Luna Innovations Incorporated Biomarker-targeting contrast agents and their use in magnetic resonance imaging for detection of atherosclerotic plaque
JP6039145B2 (ja) 2011-05-25 2016-12-07 ノバリック ゲーエムベーハー 半フッ化アルカンを基礎にした局所薬学的組成物
WO2012162664A1 (en) 2011-05-26 2012-11-29 The Trustees Of Columbia University In The City Of New York Systems and methods for opening of a tissue barrier in primates
CA2877102C (en) * 2011-06-29 2020-06-30 Avidas Pharmaceuticals Llc Topical formulations including lipid microcapsule delivery vehicles and their uses
PT2806886T (pt) 2012-01-23 2017-03-24 Novaliq Gmbh Composições de proteínas estabilizadas baseadas em alcanos semifluorados
US11116841B2 (en) 2012-04-20 2021-09-14 Klox Technologies Inc. Biophotonic compositions, kits and methods
US20130281913A1 (en) 2012-04-20 2013-10-24 Klox Technologies Inc. Biophotonic compositions and methods for providing biophotonic treatment
US20130330389A1 (en) 2012-06-08 2013-12-12 The Regents Of The University Of Michigan Ultrasound-triggerable agents for tissue engineering
WO2014031883A1 (en) 2012-08-23 2014-02-27 Susan Marie Metcalfe Neurotherapeutic nanoparticle compositions and devices
EP2895144B1 (en) 2012-09-12 2017-01-11 Novaliq GmbH Semifluorinated alkane compositions
MX363182B (es) 2012-09-12 2019-03-13 Novaliq Gmbh Composiciones que comprenden mezclas de alcanos semifluorados.
BR112015005593B1 (pt) 2012-09-14 2019-09-24 Valeant Pharmaceuticals International, Inc. Método para branqueamento de dentes
WO2014059170A1 (en) 2012-10-10 2014-04-17 The Trustees Of Columbia University In The City Of New York Systems and methods for mechanical mapping of cardiac rhythm
US20140276354A1 (en) 2013-03-14 2014-09-18 Klox Technologies Inc. Biophotonic materials and uses thereof
US9247921B2 (en) 2013-06-07 2016-02-02 The Trustees Of Columbia University In The City Of New York Systems and methods of high frame rate streaming for treatment monitoring
WO2015000058A1 (en) 2013-07-03 2015-01-08 Klox Technologies Inc. Biophotonic compositions comprising a chromophore and a gelling agent for treating wounds
DK3024484T3 (en) 2013-07-23 2018-10-08 Novaliq Gmbh STABILIZED ANTIBODY COMPOSITIONS
US10322178B2 (en) 2013-08-09 2019-06-18 The Trustees Of Columbia University In The City Of New York Systems and methods for targeted drug delivery
US10028723B2 (en) 2013-09-03 2018-07-24 The Trustees Of Columbia University In The City Of New York Systems and methods for real-time, transcranial monitoring of blood-brain barrier opening
JP2017509433A (ja) 2014-04-01 2017-04-06 クロックス テクノロジーズ インコーポレイテッドKlox Technologies Inc. 組織充填剤組成物および使用方法
EP3212826B1 (en) 2014-10-31 2020-10-14 Klox Technologies Inc. Photoactivatable fibers and fabric media
US20170087100A1 (en) 2015-09-30 2017-03-30 Novaliq Gmbh Semifluorinated compounds and their compositions
EP3722274B1 (en) 2015-09-30 2023-06-07 Novaliq GmbH 2-perfluorobutyl pentane for ophthalmic administration
WO2017062502A1 (en) * 2015-10-05 2017-04-13 The Regents Of The University Of Colorgo, A Body Corporate Lipoplexes formulated for catalytic delivery
JP2019512484A (ja) * 2016-03-07 2019-05-16 メモリアル スローン ケタリング キャンサー センター 骨髄、細網内皮系、および/またはリンパ節を標的にする放射標識リポソームならびにその診断用および治療用使用の方法
DK3442480T3 (da) 2016-06-23 2020-01-13 Novaliq Gmbh Fremgangsmåde til topisk indgivelse
KR102614858B1 (ko) 2016-09-22 2023-12-18 노바리크 게엠베하 안검염 치료에 사용되는 약제학적 조성물
AU2017329983B2 (en) 2016-09-23 2022-05-05 Novaliq Gmbh Ophthalmic compositions comprising ciclosporin
MX381639B (es) 2016-12-23 2025-03-13 Novaliq Gmbh Composicion oftalmica para el tratamiento de la enfermedad del ojo seco.
WO2018169954A1 (en) 2017-03-13 2018-09-20 Sdg, Inc. Lipid-based nanoparticles with enhanced stability
US11077173B2 (en) 2017-03-13 2021-08-03 Sdg, Inc. Lipid-based nanoparticles and methods using same
PL3612228T3 (pl) 2017-04-21 2024-04-08 Dermaliq Therapeutics, Inc. Kompozycje jodu
US11278503B2 (en) 2017-05-12 2022-03-22 Novaliq Gmbh Pharmaceutical compositions comprising semifluorinated alkanes for the treatment of contact lense-related conditions
JP7814839B2 (ja) 2017-09-27 2026-02-17 ノバリック ゲーエムベーハー 眼疾患の治療に使用するためのラタノプロストを含む眼科用組成物
CN111182893A (zh) 2017-10-04 2020-05-19 诺瓦利克有限责任公司 包含f6h8的眼用组合物
WO2019161263A1 (en) * 2018-02-16 2019-08-22 Ohio State Innovation Foundation Lipid-surfactant nanoparticles for drug delivery and methods of making and uses thereof
US11576893B2 (en) 2018-03-02 2023-02-14 Novaliq Gmbh Pharmaceutical compositions comprising nebivolol
AU2019246035B2 (en) 2018-03-28 2024-07-18 Novaliq Gmbh Pharmaceutical composition comprising timolol
JP7855312B2 (ja) 2018-04-27 2026-05-08 ノバリック ゲーエムベーハー 緑内障の治療のためのタフルプロストを含む眼科用組成物
WO2020064549A1 (en) 2018-09-27 2020-04-02 Novaliq Gmbh Lipid barrier repair
US11510855B2 (en) 2018-09-27 2022-11-29 Dermaliq Therapeutics, Inc. Topical sunscreen formulation
CA3112031A1 (en) 2018-10-12 2020-04-16 Novaliq Gmbh Ophthalmic composition for treatment of dry eye disease
EP3923907B1 (en) 2019-02-13 2024-09-25 Novaliq GmbH Compositions and methods for the treatment of ocular neovascularization
CN114449999A (zh) 2019-09-06 2022-05-06 诺瓦利克有限责任公司 用于治疗葡萄膜炎的眼用组合物
US12050255B2 (en) * 2022-02-23 2024-07-30 Saudi Arabian Oil Company Magnetically activated acoustic nanotracers
AU2024398257A1 (en) * 2023-12-14 2026-07-09 Sonothera, Inc. Methods and systems for improved nucleic acid delivery via ultrasound

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7083572B2 (en) * 1993-11-30 2006-08-01 Bristol-Myers Squibb Medical Imaging, Inc. Therapeutic delivery systems
US5690907A (en) * 1995-06-08 1997-11-25 The Jewish Hospital Of St. Louis Avidin-biotin conjugated emulsions as a site specific binding system
US6548046B1 (en) * 1995-06-08 2003-04-15 Barnes-Jewish Hospital Site specific binding system, imaging compositions and methods
US5780010A (en) * 1995-06-08 1998-07-14 Barnes-Jewish Hospital Method of MRI using avidin-biotin conjugated emulsions as a site specific binding system
US6821506B2 (en) * 1995-06-08 2004-11-23 Barnes-Jewish Hospital Site specific binding system, imaging compositions and methods
US6896659B2 (en) * 1998-02-06 2005-05-24 Point Biomedical Corporation Method for ultrasound triggered drug delivery using hollow microbubbles with controlled fragility
US6676963B1 (en) * 2000-10-27 2004-01-13 Barnes-Jewish Hospital Ligand-targeted emulsions carrying bioactive agents
US6716168B2 (en) * 2002-04-30 2004-04-06 Siemens Medical Solutions Usa, Inc. Ultrasound drug delivery enhancement and imaging systems and methods
US20030215394A1 (en) * 2002-05-17 2003-11-20 Short Robert E. Microparticles having a matrix interior useful for ultrasound triggered delivery of drugs into the bloodstream
US7358226B2 (en) * 2003-08-27 2008-04-15 The Regents Of The University Of California Ultrasonic concentration of drug delivery capsules

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012508190A (ja) * 2008-11-07 2012-04-05 クロクス テクノロジーズ インコーポレイテッド ヒアルロン酸、グルコサミン、およびアラントインを含む、酸化的光活性化皮膚再生組成物
JP2012508189A (ja) * 2008-11-07 2012-04-05 クロクス テクノロジーズ インコーポレイテッド 創傷治癒のための酸化剤および光活性化剤の組み合わせ
JP2013253110A (ja) * 2008-11-07 2013-12-19 Klox Technologies Inc ヒアルロン酸、グルコサミン、およびアラントインを含む、酸化的光活性化皮膚再生組成物
JP2013253109A (ja) * 2008-11-07 2013-12-19 Klox Technologies Inc 創傷治癒のための酸化剤および光活性化剤の組み合わせ
JP2016006120A (ja) * 2008-11-07 2016-01-14 クロクス テクノロジーズ インコーポレイテッド 創傷治癒のための酸化剤および光活性化剤の組み合わせ
JP2016020386A (ja) * 2008-11-07 2016-02-04 クロクス テクノロジーズ インコーポレイテッド ヒアルロン酸、グルコサミン、およびアラントインを含む、酸化的光活性化皮膚再生組成物
JP2016193951A (ja) * 2008-11-07 2016-11-17 クロクス テクノロジーズ インコーポレイテッド 創傷治癒のための酸化剤および光活性化剤の組み合わせ
JP2016193950A (ja) * 2008-11-07 2016-11-17 クロクス テクノロジーズ インコーポレイテッド ヒアルロン酸、グルコサミン、およびアラントインを含む、酸化的光活性化皮膚再生組成物
JP2012533522A (ja) * 2009-07-17 2012-12-27 クロクス テクノロジーズ インコーポレイテッド 口腔内消毒および口腔疾患の処置のための酸化剤、光増感剤および創傷治癒剤の組み合わせ

Also Published As

Publication number Publication date
EP1684724A2 (en) 2006-08-02
CA2540621A1 (en) 2005-06-09
IL174690A0 (en) 2006-08-20
AU2004293027A1 (en) 2005-06-09
WO2005051305A2 (en) 2005-06-09
US20050175541A1 (en) 2005-08-11
WO2005051305A3 (en) 2005-08-04
EP1684724A4 (en) 2008-04-02

Similar Documents

Publication Publication Date Title
JP2007511616A5 (cg-RX-API-DMAC7.html)
US20050175541A1 (en) Enhanced drug delivery
US20050079131A1 (en) Emulsion particles for imaging and therapy and methods of use thereof
JP4202139B2 (ja) 温度依存性造影剤による強化型超音波検出
DE69831755T2 (de) Optoakustische kontrastmittel und anwendungsverfahren
US20070258908A1 (en) Detection and imaging of target tissue
DE69632401T2 (de) Neue zielgerichtete mittel zur diagnostischen und therapeutischen verwendung
CN100563718C (zh) 用于反差成像的充气微囊组件
AU2002240177A1 (en) Enhanced ultrasound detection with temperature dependent contrast agents
US20070128117A1 (en) Ultrasound contrast agents and process for the preparation thereof
US20110014124A1 (en) Targeted atherosclerosis treatment
US20230066723A1 (en) Microparticle compositions
WO2017190108A1 (en) Compositions and methods for targeted contrast agents for molecular imaging
JP2013532681A (ja) 抗原特異的超音波造影剤、その調製方法及びその使用
AU2007201577B2 (en) Enhanced ultrasound detection with temperature-dependent contrast agents
Lukáč Micro and Nanoparticles as Drug Carriers: Surface-Modified Microbubbles Used as Ultrasound Contrast Agents and Drug Carriers

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071015

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20071015

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20091116